Health Care · Biological Products, (No Diagnostic Substances)

IKT Inhibikase Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 175014972 filings
Russell 2000

IKT at a glance

Inhibikase Therapeutics, Inc. (IKT, SEC CIK 1750149) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as October 21, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2024 (FY2024), Inhibikase Therapeutics, Inc. (IKT) reported revenue of $0 and a net loss of $27.5 million. Diluted EPS was -$1.16.
  • As of September 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Inhibikase Therapeutics, Inc. (IKT) shares worth $63.0 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2024
$0
10-K XBRL
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
22 funds
$63.0M · +0 vs prior quarter
Latest 8-K
Nov 10, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • China-related regulation: BIOSECURE Act restrictions could force transition from WuXi AppTec subsidiary STA, delaying IKT-001 supply
  • Most material update: WuXi AppTec added to Section 1260H list in June 2026, with designation challenged and preliminarily enjoined August 7, 2026
  • Compliance risk: proposed restrictions on China-based clinical data could limit trial-site use and increase development costs
  • Operational risk: third-party manufacturing deviations or scale-up failures could delay clinical trials and product launches
  • Supply-chain concentration: STA Pharmaceutical Hong Kong manufactures and supplies IKT-001 drug substance and drug product

Management Discussion & Analysis

  • Quarterly revenue $0, unchanged YoY, no commercial product sales
  • Net loss $20.5M vs $11.9M YoY, operating loss $22.2M vs $12.8M
  • PAH R&D $12.5M vs $5.6M, strongest program, Parkinson’s R&D $0 vs $0.3M
  • Cash, equivalents and marketable securities $193.3M at September 30, 2026
  • Nine-month operating cash use $41.9M vs $20.3M, financing provided $53.3M
  • Outlook: funding expected through topline Phase 3 readout, additional capital likely needed due to ongoing losses

AI summary of the IKT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 10, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026
  • Corporate updates announced alongside quarterly results

Item EX-99.1: Item EX-99.1

  • Phase 3 IMPROVE-PAH advancing: 28 countries approved and 79 of 180 planned sites activated
  • Part A interim safety readout planned for first half of 2027, a near-term clinical catalyst
Filed Oct 20, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Dennis Berman resigned as director and Compensation Committee Chair on October 19, 2026
  • Scott Wasserman appointed independent Class III director through 2029 annual meeting

Item EX-99.1: Item EX-99.1

  • Scott Wasserman appointed director effective October 19, 2026, replacing departing director Dennis Berman
  • Experienced cardiovascular and metabolic drug developer, including leadership of Repatha, Evenity and Aimovig programs

Item 7.01: Regulation FD Disclosure

  • Scott Wasserman appointed to Inhibikase Therapeutics’ board of directors
  • Board appointment may influence governance, strategic oversight and shareholder confidence
Filed Sep 8, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Phase 3 IMPROVE-PAH enrolling across 26 countries and 46 of 180 planned sites, validating late-stage execution
  • IKT-001 targets PAH, a disease with approximately 30% five-year mortality and an estimated $8.3B antiproliferative market

Item 7.01: Regulation FD Disclosure

  • Updated corporate presentation for investor and analyst meetings
  • Presentation materials furnished as Exhibit 99.1

AI summaries of IKT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for IKT

Don't miss the next IKT filing

  • Alerts as it files. A push when IKT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut IKT, by share count.
  • Ask anything. An AI agent that reads every IKT filing and answers with sources.

IKT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Wasserman Scott M.AOct 19, 2026-
BERMAN DENNIS NMJul 30, 2026$1.26
BERMAN DENNIS NMJul 30, 2026-
RA CAPITAL MANAGEMENT, L.P.JJul 29, 2026-
RA CAPITAL MANAGEMENT, L.P.JJul 29, 2026-
Aurentz VincentAJun 26, 2026-
BERMAN DENNIS NAJun 26, 2026-
Kush ArvindAJun 26, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$0-
Operating Income-$20.1M-$28.6M-$52.0M
Net Income-$19.0M-$27.5M-$48.3M
Balance Sheet
Total Assets$14.5M$98.6M$181.2M
Equity-$94.9M$172.9M
ROE--29.0%-27.9%
Per Share
EPS$-3.57$-1.16$-0.49
Cash Flow
Operating CF--$19.1M-$27.8M
CapEx$14K$0$13K

Source: XBRL data in Inhibikase Therapeutics, Inc. (IKT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate IKT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
IKT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202622$63.0M
Q2 202622$58.7M
Q1 202623$43.9M
Q4 202519$37.0M
Q3 202517$17.0M
Q2 202515$19.4M
Q1 20259$13.5M
Q4 20246$16.8M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 133 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

IKT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 10, 2026Analysis-
10-QNov 10, 2026Analysis
4Oct 21, 2026--
8-KOct 20, 2026Analysis-
8-KSep 8, 2026Analysis-
8-KAug 26, 2026Analysis-
8-KAug 11, 2026Analysis-
10-QAug 11, 2026Analysis
4Jul 31, 2026--
4Jul 31, 2026--
8-KJul 29, 2026Analysis-
SC 13GJul 28, 2026-
8-KJul 23, 2026Analysis-
SC 13GJul 17, 2026-
8-KJul 14, 2026Analysis-
4Jun 30, 2026--
4Jun 30, 2026--
4Jun 30, 2026--
4Jun 30, 2026--
4Jun 30, 2026--
4Jun 30, 2026--
8-KJun 29, 2026Analysis-
8-KMay 12, 2026Analysis
10-QMay 12, 2026Analysis
8-KApr 7, 2026Analysis-

Related Health Care companies

All Health Care →

IKT SEC filings: frequently asked questions

Which institutions hold IKT stock?

As of September 30, 2026, the largest Inhibikase Therapeutics, Inc. (IKT) holders among the 13F filers tracked by SignalX were BlackRock ($17.6 million), Blackstone Group ($11.9 million), Vanguard Capital Management LLC ($10.4 million), Millennium Management ($8.2 million), State Street Corp ($4.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was IKT's revenue in fiscal year 2024?

For the fiscal year ended December 31, 2024 (FY2024), Inhibikase Therapeutics, Inc. (IKT) reported revenue of $0 and a net loss of $27.5 million. Diluted EPS was -$1.16. The figures come from the XBRL data in the 10-K.

What did IKT report in its latest 8-K?

Inhibikase Therapeutics, Inc. (IKT) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026.

What are the latest IKT SEC filings?

Inhibikase Therapeutics, Inc. (IKT) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on October 21, 2026.

What is IKT's SEC CIK number?

Inhibikase Therapeutics, Inc. (IKT)'s SEC Central Index Key (CIK) is 1750149. EDGAR lists every IKT filing under that number.

Ask anything about IKT

The research agent reads IKT's filings, financials, insider trades and 13F holders, then answers with sources.